Lung Cancer Treatment

April 10, 2025

Tissue Agnostic – Genomic Based Treatment – A Paradigm Shift in Cancer Treatment

Charles H. Weaver, MD
September 17, 2024

Targeted Therapies Show Promise in Early Phase Trials

Charles H. Weaver, MD
August 18, 2024

ASCO 2024 – Major Advances in the Treatment of Lung Cancer

Charles H. Weaver, MD
February 2, 2024

Targeting KRAS G12C mutations in colon, lung, and other cancers

Charles H. Weaver, MD
November 16, 2023

Treatment of ROS1+ NSCLC with Augtyro (repotrectinib)

Charles H. Weaver, MD
November 8, 2023

Learn how ctDNA testing can help inform management of lung cancer

Charles H. Weaver, MD
October 22, 2023

Antibody Drug Conjugates Bispecific Antibodies and Lung Cancer

Charles H. Weaver, MD
October 17, 2023

The Importance of NGS-Biomarker Testing in Lung Cancer

Charles H. Weaver, MD
September 15, 2023

Patritumab Deruxtecan in EGFR-Mutated NSCLC

Charles H. Weaver, MD
March 11, 2022

RFA and SBRT Treatment of Lung Cancer

Charles H. Weaver, MD
September 11, 2021

TILs + Opdivo Produce Remissions in Advanced Lung Cancer

Charles H. Weaver, MD
March 11, 2021

Rozlytrek Precision Cancer Medicine Effectively Targets ROS 1 NSCLC

Charles H. Weaver, MD